Skaidrius Miliauskas

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

Tudor–Eliade Ciuleanu, Lilia Stelmakh, Saulius Cicėnas et al. · The Lancet Oncology · 2012 · 373 citations

Medicine, Oncology, Pharmacology +13

RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Gérald Simonneau, Andrea Maria D’Armini, Peter F. Fedullo et al. · The Lancet Respiratory Medicine · 2017 · 264 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer

Jurgita Jackutė, Marius Žemaitis, Darius Pranys et al. · BMC Immunology · 2018 · 261 citations · Full text

Medicine, Immunology, Oncology +17

Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry

Marius M. Hoeper, Christine Pausch, Ekkehard Grünig et al. · The Journal of Heart and Lung Transplantation · 2020 · 207 citations · Full text

Medicine, Cardiology, Clinical Epidemiology +10

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

Thomas M. File, Donald E. Low, Paul B. Eckburg et al. · Journal of Antimicrobial Chemotherapy · 2011 · 196 citations · Full text

Medicine, Infectious Diseases, Pharmacology +13